Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.

"raw reads and processed rna-seq gene counts generated for this study are available at gene expression omnibus accession number gse240444."

"Competing interests The authors declare no competing interests."

"We are grateful to the patients who contributed samples and clinical information used to derive the PDX lines used in this study. We thank Amy Schmidt for technical assistance and Jackie Tucker-Davis for animal care. We also thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital (St. Louis, MO) for the use of the Siteman Flow Cytometry Core which provided cell sorting expertise; Grant Challen (St. Louis, MO) who provided the MOLT-3 cell line; Roche (Basel, Switzerland) which provided idasanutlin (RG7388) for investigational use; and the Public Repository of Xenografts which provided xenograft lines (Boston, MA). We thank the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine for help with genomic analysis, specifically RNA sequencing. The GTAC is partially supported by NCI Cancer Center Support Grant P30 CA91842 to the Siteman Cancer Center from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. We thank the Genome Engineering & Stem Cell Center at the McDonnell Genome Institute at Washington University School of Medicine for help with mycoplasma testing and STR profiling. This work was supported by the NIH, specifically National Heart, Lung, and Blood Institute National Research Service Award Training Program in Molecular Hematology (T32 HL007088) and National Institute of General Medical Sciences National Research Service Award Training Program-Medical Scientist (T32 GM007200), both to KBJ; the Eunice Kennedy Shriver National Institute of Child Health and Human Development Training Program in Developmental Hematology (T32 HD007499) to MSZ; as well as National Cancer Institute Specialized Programs of Research Excellence in Leukemia (P50 CA171963) to DCL."